Hence then, the article about new late breaking results from phase 3 trials of skyrizi risankizumab evaluating long term effect on skin and joint symptoms in patients with psoriatic arthritis at week 100 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100 )
Also on site :
- The Iran War Hits Your Pocket
- Fall 2026 TV: The Ultimate Return Guide for Every Cop, Medical and Legal Drama
- Germany warns of world economic ‘catastrophe’; OECD cuts UK growth forecast